Unveiling the potential of novel indol-3-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE/BACE 1 dual inhibitors: a combined <i>in silico</i>, synthesis and <i>in vitro</i> study-Reference-Cited by-同舟云学术

Unveiling the potential of novel indol-3-yl-phenyl allylidene hydrazine carboximidamide derivatives as AChE/BACE 1 dual inhibitors: a combined in silico, synthesis and in vitro study

Published:2024 Issue:33 Volume:14 Page:23853-23872
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Sharma Amit¹^ORCID,Rudrawar Santosh²³,Sharma Ankita⁴,Bharate Sandip B.⁴,Jadhav Hemant R.¹^ORCID

Affiliation:

1. Pharmaceutical Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Vidya Vihar, Pilani – 333031, RJ, India

2. The Institute for Biomedicine and Glycomics, Griffith University, Gold Coast 4222, Australia

3. School of Pharmacy and Medical Sciences, Griffith University, Gold Coast 4222, Australia

4. Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu – 181110, India

Abstract

Considering the failure of many enzyme inhibitors for Alzheimer's disease (AD), research is now focused on multi-target directed drug discovery.

Funder

Birla Institute of Technology and Science, Pilani

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D4RA04315D

Reference29 articles.

1. Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress

2. https://www.who.int , accessed on 04-04-2024

3. Synthesis and Evaluation of Multi-Target-Directed Ligands against Alzheimer’s Disease Based on the Fusion of Donepezil and Ebselen

4. Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer’s disease

5. Alzheimer's disease drug development pipeline: 2017